View Post

USC Opens Phase II Trial of Ambrx’s ARX788 for HER2-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: precisiononcologynews.com The University of Southern California’s Norris Comprehensive Cancer Center on Monday said it has opened a Phase II trial of Ambrx’s antibody-drug conjugate ARX788 for advanced HER2-positive breast cancer patients. The trial, which is sponsored by La Jolla, California-based Ambrx, will involve roughly 200 HER2-positive metastatic breast cancer patients who have previously received trastuzumab emtansine (Genentech’s Kadcyla; T-DM1), …

View Post

Tyme Technologies Begins Cancer Metabolism-Based Therapy Trial in Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Tyme Technologies said on Monday it has dosed the first patient in its Phase II OASIS trial of SM-88 in previously treated metastatic hormone receptor (HR)-positive HER2-negative breast cancer patients. The investigator-initiated study at Georgetown University will initially enroll 30 patients with metastatic HR-positive HER2-negative breast cancer who have previously received at least two lines …

View Post

PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC

In Clinical Studies News by Barbara Jacoby

Source: PharmAbcine From: prnewswire.com PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II combination trial of olinvacimab, PharmAbcine’s anti-VEGFR2 antibody, and KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 molecule, for the treatment of metastatic Triple-Negative Breast Cancer (mTNBC) in …

View Post

Allarity Therapeutics Begins European Study of Ixempra for Biomarker-Selected Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Allarity Therapeutics on Thursday said that it has enrolled the first patient in a European Phase II clinical trial evaluating the microtubulin inhibitor ixabepilone (Ixempra) as a third-line treatment for certain metastatic breast cancers. Specifically, Allarity — previously named Oncology Venture — will evaluate the agent, a product for which it in-licensed the European rights …

View Post

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Matthew Fowler From: cancernetwork.com The PHERGain II trial will investigate the treatment of patients with early HER2-positive breast cancer using a chemotherapy-free treatment approach of trastuzumab plus pertuzumab. A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is as effective as the current standard of …

View Post

Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

In Clinical Studies News by Barbara Jacoby

From: businesswire.com – Trial will evaluate the efficacy and safety of Pfizer’s targeted therapies, VIZIMPRO® and XALKORI®, in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test – First clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology company …

View Post

Seven-year Data Shows Accuray TomoTherapy® System Provides Excellent Long-Term Control of Low-Risk Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Accuray Incorporated From: prnewswire.com Advanced, 10-Day Radiation Treatment Regimen Enables Patients to Get Back to Their Life, Faster Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation (APBI) delivered with the …

View Post

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

In In The News by Barbara Jacoby

From: businesswire.combreast Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Latest findings from the breast cancer cohort in SUMMIT – a phase 2 ‘basket’ trial of neratinib + trastuzumab + …

View Post

Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™

In Clinical Studies News by Barbara Jacoby

Source: Natera, Inc. From: prnewswire.com Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE®), a CDK4/6 inhibitor developed by Pfizer for the treatment of HR-positive, HER2-negative advanced breast cancer when given in combination with …

View Post

Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Natera, Inc. From: prnewswire.com Study to use Signatera™ to test effectiveness of Ribociclib in combination with endocrine therapy versus standard endocrine therapy Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a collaborative agreement with Mass General Cancer Center (MGCC) of Massachusetts General Hospital, related to an investigator-initiated multi-center, Phase II randomized clinical trial of …